Xoma raises $40 million in follow-on

Xoma Corp. (NASDAQ:XOMA) raised $40 million in a follow-on underwritten by Credit Suisse and Cowen. Xoma's gevokizumab is in Phase III testing for non-infectious uveitis and Behcet's uveitis. Gevokizu...